Trigger-happy AstraZeneca (NYSE:AZN) is done waiting for home-grown talent to develop. In recent weeks, the Big Pharma laggard has acquired Omthera (NASDAQ:OMTH) and Pearl Therapeutics. These acquisitions instantly inject one promising late-stage drug into the  pipeline, one drug facing regulatory approval into the product mix, and a few others in earlier stages of development. The company has thrust itself into competing in two major markets virtually overnight. This is certainly a welcomed sight for investors, who have experienced their fair share of disappointment in recent quarters. The moves don't put AstraZeneca on the same level as more successful peers, but it is a great start to getting back on the right track. In the following video, Fool contributor Maxx Chatsko explains what the moves mean for investors. 

Fool contributor Maxx Chatskohas no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.